

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

GDM-1

RRID:CVCL_1230

Type: Cell Line

Proper Citation

RRID:CVCL_1230

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1230

Proper Citation: RRID:CVCL_1230

Sex: Female

Defining Citation: [PMID:6296552](#), [PMID:16408098](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23955599](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Derived from sampling site: Peripheral blood., Misspelling: GMD-1; In Cosmic 2131537., Omics: Transcriptome analysis., Omics: SNP array analysis., Omics: DNA methylation analysis., Omics: Deep RNAseq analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Microsatellite instability: Stable (MSS) (Sanger)., Doubling time: 96-12 hours (PubMed=6296552); ~40-50 hours (DSMZ)., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: GDM-1

Synonyms: GDM1

Cross References: CLO:CLO_0003467, EFO:EFO_0002183, CLDB:cl1446, CLDB:cl5541, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2627, BioSample:SAMN03473160, BioSample:SAMN10987916, Cell_Model_Passport:SIDM01057, CGH-DB:9221-4, ChEMBL-Cells:ChEMBL3308198, ChEMBL-Targets:ChEMBL2366157, Cosmic:787430, Cosmic:906870, Cosmic:947368, Cosmic:975249, Cosmic:999777, Cosmic:1012067, Cosmic:1177802, Cosmic:1197932, Cosmic:1281313, Cosmic:2089666, Cosmic:2131537, Cosmic:2306196, Cosmic-CLP:906870, DepMap:ACH-000081, DSMZ:ACC-87, DSMZCellDive:ACC-87, EGA:EGAS00001000978, GDSC:906870, GEO:GSM887023,

GEO:GSM888093, GEO:GSM1446735, GEO:GSM1669808, ICLC:HTL01008, IARC_TP53:21342, IGRhCellID:GDM1, LiGeA:CCLE_860, LINCS_LDP:LCL-1052, PharmacDB:GDM1_402_2019, PRIDE:PXD030304, Progenetix:CVCL_1230, PubChem_Cell_line:CVCL_1230, Wikidata:Q54835529

ID: CVCL_1230

Record Creation Time: 20220427T215858+0000

Record Last Update: 20260913T003127+0000

Ratings and Alerts

No rating or validation information has been found for GDM-1.

No alerts have been found for GDM-1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. *Cell stem cell*, 33(6), 982.

Cho HJ, et al. (2025) SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. *EMBO molecular medicine*, 17(8), 2115.

Emdal KB, et al. (2022) Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance. *Cell reports*, 40(6), 111177.

Hernandez-Malmierca P, et al. (2022) Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. *Cell stem cell*, 29(5), 760.

Aho ER, et al. (2019) Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. *Cell reports*, 26(11), 2916.